PROGRAM
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
PARTNER TERRITORY
Type 1 Diabetes
JDRF
CFRD
Type 2 Diabetes
Cystic Fibrosis Foundation
Huadong Medicine
China and Pac Rim (excl. Japan)
SAD/MAD Completed
Psoriasis
COPD
Atopic Dermatitis
China and Pac Rim (excl. Japan)
China and Pac Rim (excl. Japan)
China and Pac Rim (excl. Japan)
HPP593
PPAR-δ activator
Primary Mitochondrial Myopathy
Worldwide
Azeliragon
RAGE antagonist
Pancreatic Cancer
Worldwide
Renal Diseases
Anteris Bio
Worldwide
Undisclosed
TTP-RA
RAGE antagonist
T1D Prevention
vTv
Partnered

Notes:
TTP399:  vTv has worldwide rights
TTP273:  Huadong has rights for China and Pacific Rim Rights, excluding Japan
HPP737: Newsoara has rights for China and Pacific Rim Rights, excluding Japan
HPP593: Reneo has worldwide rights with vTv having equity interest in Reneo
Azeliragon:  Cantex has worldwide rights
HPP971: Anteris Bio has worldwide rights with vTv having equity interest in Anteris
HPP3033:  vTv has worldwide rights
TTPRA:  vTv has worldwide rights